Empagliflozin in heart failure without diabetes
Phase 3
Recruiting
- Conditions
- Heart Failure.Heart failure
- Registration Number
- IRCT20210828052313N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
35<EF<50
Exclusion Criteria
DM
GFR<30
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ejection fraction. Timepoint: At the beginning of the study and 6 months after starting the drug. Method of measurement: Echocardiography.;Quality of life. Timepoint: At the beginning of the study and 6 months after starting the drug. Method of measurement: kansas city cardiomyopathy questionnaire.
- Secondary Outcome Measures
Name Time Method aboratory finding. Timepoint: The beginning of the study and six months after starting the medication. Method of measurement: Laboratory measurement.